{
    "data": [
        {
            "id": "640f857d201352f04a00002b_0001",
            "question": "What is CHARMS with respect to medical review of predictive modeling?",
            "type": "factoid",
            "context": "CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS)."
        },
        {
            "id": "640f857d201352f04a00002b_0002",
            "question": "What is CHARMS with respect to medical review of predictive modeling?",
            "type": "factoid",
            "context": "We will extract data based on the Checklist for\u00a0Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS), "
        },
        {
            "id": "640f857d201352f04a00002b_0003",
            "question": "What is CHARMS with respect to medical review of predictive modeling?",
            "type": "factoid",
            "context": "Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS-PF)."
        },
        {
            "id": "640f857d201352f04a00002b_0004",
            "question": "What is CHARMS with respect to medical review of predictive modeling?",
            "type": "factoid",
            "context": "Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS)"
        },
        {
            "id": "6410eb95201352f04a00002e_0001",
            "question": "Which splicing factors have been associated with alternative splicing in PLN R14del hearts?",
            "type": "list",
            "context": "Our work suggests that an intricate interplay of programs controlling gene expression levels and AS is fundamental to organ development, especially for the brain and heart."
        },
        {
            "id": "6410eb95201352f04a00002e_0002",
            "question": "Which splicing factors have been associated with alternative splicing in PLN R14del hearts?",
            "type": "list",
            "context": "Bioinformatical analysis pointed to the tissue-specific splicing factors Srrm4 and Nova1 as likely upstream regulators of the observed splicing changes in the PLN-R14del cardiomyocytes. "
        },
        {
            "id": "64162fb0690f196b5100001a_0001",
            "question": "What are the most common mutation types in Duchenne muscular Dystrophy?",
            "type": "list",
            "context": " 64% deletions, 18% duplications and 18% point mutations. "
        },
        {
            "id": "64162fb0690f196b5100001a_0002",
            "question": "What are the most common mutation types in Duchenne muscular Dystrophy?",
            "type": "list",
            "context": "Of these, 406 (70.5%) were exonic deletions, 64 (11.1%) were exonic duplications, and one was a deletion/duplication complex rearrangement (0.2%). Small mutations were identified in 105 cases (18.2%), most being nonsense/frameshift types (75.2%). Mutations in splice sites, however, were relatively frequent (20%). "
        },
        {
            "id": "64162fb0690f196b5100001a_0003",
            "question": "What are the most common mutation types in Duchenne muscular Dystrophy?",
            "type": "list",
            "context": "gene deletion rate was 54.3% (391/720), and gene duplication rate was 10.6% (76/720)"
        },
        {
            "id": "64162fb0690f196b5100001a_0004",
            "question": "What are the most common mutation types in Duchenne muscular Dystrophy?",
            "type": "list",
            "context": "The rate of deletion mutant occurred in Exon 45-54 was 71.9% (281/391) in all gene deletion patients; meanwhile, the rate of gene duplication occurred in Exon 1-40 was 82.9% (63/76) in all gene duplication ones."
        },
        {
            "id": "64162fb0690f196b5100001a_0005",
            "question": "What are the most common mutation types in Duchenne muscular Dystrophy?",
            "type": "list",
            "context": "In all the patients with gene deletion and duplication, the rate of DMD and IMD was 90.6% (423/467), and BMD, 9.4% (44/467)."
        },
        {
            "id": "64162fb0690f196b5100001a_0006",
            "question": "What are the most common mutation types in Duchenne muscular Dystrophy?",
            "type": "list",
            "context": "The Duchenne Muscular dystrophy (DMD) is the most frequent muscle disorder in childhood caused by mutations in the Xlinked dystrophin gene (about 65% deletions, about 7% duplications, about 26% point mutations and about 2% unknown mutations). "
        },
        {
            "id": "63eef3ebf36125a42600000a_0001",
            "question": "What is the target of Litifilimab?",
            "type": "factoid",
            "context": "Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus."
        },
        {
            "id": "63eef3ebf36125a42600000a_0002",
            "question": "What is the target of Litifilimab?",
            "type": "factoid",
            "context": "Whether treatment with litifilimab, a humanized monoclonal antibody against BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied."
        },
        {
            "id": "63eef3ebf36125a42600000a_0003",
            "question": "What is the target of Litifilimab?",
            "type": "factoid",
            "context": "Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus."
        },
        {
            "id": "63eef3ebf36125a42600000a_0004",
            "question": "What is the target of Litifilimab?",
            "type": "factoid",
            "context": " The safety and efficacy of subcutaneous litifilimab, a humanized monoclonal antibody that binds to BDCA2, in patients with SLE have not been extensively studied."
        },
        {
            "id": "64136fbf201352f04a00003d_0001",
            "question": "What is area under the receiver operating characteristic curve in context of predictive modeling?",
            "type": "factoid",
            "context": ". The area under the receiver operator characteristics curve (area under the receiver operating characteristic curve)"
        },
        {
            "id": "64136fbf201352f04a00003d_0002",
            "question": "What is area under the receiver operating characteristic curve in context of predictive modeling?",
            "type": "factoid",
            "context": "area under receiver operator curve [area under the receiver operating characteristic curve] "
        },
        {
            "id": "64136fbf201352f04a00003d_0003",
            "question": "What is area under the receiver operating characteristic curve in context of predictive modeling?",
            "type": "factoid",
            "context": "The model performance was evaluated using the area under the receiver operating characteristic curve (area under the receiver operating characteristic curve)"
        },
        {
            "id": "64136664201352f04a00003b_0001",
            "question": "What are the main clinical features of small-fiber neuropathy (small fiber neuropathy)?",
            "type": "list",
            "context": " Selective small fiber neuropathy (without large fiber affection) manifests with pain, sensory disturbances, or autonomic dysfunction. T"
        },
        {
            "id": "64136664201352f04a00003b_0002",
            "question": "What are the main clinical features of small-fiber neuropathy (small fiber neuropathy)?",
            "type": "list",
            "context": "Neuropathic pain (Neuropathic pain) is a main feature of Fabry disease (Fabry disease) as consequence of small fiber neuropathy. Restless legs syndrome (Restless legs syndrome) in Fabry disease was not described, but it is an important feature in other small fiber neuropathies"
        },
        {
            "id": "64136664201352f04a00003b_0003",
            "question": "What are the main clinical features of small-fiber neuropathy (small fiber neuropathy)?",
            "type": "list",
            "context": "mall fiber neuropathy (small fiber neuropathy) can be associated with autoantibodies, including those of IgM class with specificity for the trisulfated heparan disaccharide (Trisulfated Heparin Disaccharide) antigen."
        },
        {
            "id": "64136664201352f04a00003b_0004",
            "question": "What are the main clinical features of small-fiber neuropathy (small fiber neuropathy)?",
            "type": "list",
            "context": "Up to 50% of small fiber neuropathy (small fiber neuropathy) cases are idiopathic, but novel antibodies to Trisulfated Heparin Disaccharide (Trisulfated Heparin Disaccharide) and fibroblast growth factor receptor 3 (FGFR-3) have been implicated in half of these cases"
        },
        {
            "id": "6415c53e690f196b51000012_0001",
            "question": "When was Keytruda approved by the Food and Drug Administration for the treatment of metastatic non-small cell lung cancer?",
            "type": "factoid",
            "context": "On October 24, 2016, the U.S. Food and Drug Administration (Food and Drug Administration) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (metastatic non-small cell lung cancer) whose tumors express programmed death-ligand 1 (programmed death-ligand 1) as determined by an Food and Drug Administration-approved test, as follows: (a) first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have high programmed death-ligand 1 expression (tumor proportion score [tumor proportion score] \u226550%), with no epidermal growth factor receptor (epidermal growth factor receptor) or anaplastic lymphoma kinase (anaplastic lymphoma kinase) genomic tumor aberrations, and (b) treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1 (tumor proportion score \u22651%), with disease progression on or after platinum-containing chemotherapy. "
        },
        {
            "id": "6417949d690f196b51000035_0001",
            "question": "Which gene therapies are under investigation for Duchenne muscular dystrophy?",
            "type": "list",
            "context": " In relation to clinical trials, in the last ten years, has experienced great advances in the field of therapeutic options, divided into two major therapeutic targets: 1) the area of gene therapies and 2) trying to reverse or block the pathophysiological processes of the disease, such as inflammation, fibrosis, muscle regeneration, etc. "
        },
        {
            "id": "6417949d690f196b51000035_0002",
            "question": "Which gene therapies are under investigation for Duchenne muscular dystrophy?",
            "type": "list",
            "context": "Several promising gene therapies are currently under investigation. These include gene replacement, exon skipping, suppression of stop codons."
        },
        {
            "id": "6417949d690f196b51000035_0003",
            "question": "Which gene therapies are under investigation for Duchenne muscular dystrophy?",
            "type": "list",
            "context": "More recently, a promising gene editing tool referred to as CRISPR/Cas9 offers exciting perspectives for restoring dystrophin expression in patients with DMD."
        },
        {
            "id": "6417949d690f196b51000035_0004",
            "question": "Which gene therapies are under investigation for Duchenne muscular dystrophy?",
            "type": "list",
            "context": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation have emerged, making great strides in uncovering barriers to gene therapies for DMD and other genetic diseases"
        },
        {
            "id": "641368ee201352f04a00003c_0001",
            "question": "What are the  types/categories of adult diffuse gliomas.",
            "type": "list",
            "context": " Adult-type diffuse gliomas are genetically defined and include astrocytoma, isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant, oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q codeleted, and glioblastoma, isocitrate dehydrogenase-wildtype"
        },
        {
            "id": "641368ee201352f04a00003c_0002",
            "question": "What are the  types/categories of adult diffuse gliomas.",
            "type": "list",
            "context": " According to the 2021 World Health Organization classification, the three risk types included (1) low-risk, expecting oligodendroglioma, isocitrate dehydrogenase (isocitrate dehydrogenase)-mutant, and 1p/19q-codeleted; (2) intermediate-risk, expecting astrocytoma, isocitrate dehydrogenase-mutant; and (3) high-risk, expecting glioblastoma, isocitrate dehydrogenase-wildtype."
        },
        {
            "id": "6415bc8d690f196b5100000f_0001",
            "question": "What is the estimated reduction in time when using online genetic counseling?",
            "type": "factoid",
            "context": "We estimated reduced time and costs by online counseling with about 8% and 10-12%, respectively. "
        },
        {
            "id": "6402bc2d201352f04a000005_0001",
            "question": "What are the targets of Mosunetuzumab?",
            "type": "list",
            "context": "They combine two different monospecific antigen-binding regions that target CD20 on B cells and engage T cells via CD3 in a 1:1 or 2:1 CD20:CD3 antigen binding fragment (Fab) format. The results of different phase 1 trials with BsAbs, including mosunetuzumab, glofitamab, epcoritamab and odeonextamab, have been recently published."
        },
        {
            "id": "6402bc2d201352f04a000005_0002",
            "question": "What are the targets of Mosunetuzumab?",
            "type": "list",
            "context": "Mosunetuzumab (Lunsumio\u00ae), an anti-CD20/CD3 T-cell engaging bispecific antibody, is being developed by Roche for the treatment of relapsed or refractory follicular lymphoma. "
        },
        {
            "id": "6402bc2d201352f04a000005_0003",
            "question": "What are the targets of Mosunetuzumab?",
            "type": "list",
            "context": "BACKGROUND: Mosunetuzumab is a CD20\u2009\u00d7\u2009CD3 T-cell-engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells. I"
        },
        {
            "id": "6402bc2d201352f04a000005_0004",
            "question": "What are the targets of Mosunetuzumab?",
            "type": "list",
            "context": "However, several CD20 \u00d7 CD3 BsAbs including odronextamab, mosunetuzumab, glofitamab, and epcoritamab emerged recently. "
        },
        {
            "id": "6415c6b6690f196b51000015_0001",
            "question": "On which two clinical trials was the approval of Keytruda based?",
            "type": "list",
            "context": "Approval was based on two randomized, open-label, active-controlled trials demonstrating statistically significant improvements in progression-free survival (progression-free survival) and overall survival (overall survival) for patients randomized to pembrolizumab compared with chemotherapy. In KEYNOTE-024, patients with previously untreated metastatic non-small cell lung cancer who received pembrolizumab (200 mg intravenously [intravenously] every 3 weeks) had a statistically significant improvement in overall survival (hazard ratio [hazard ratio] 0.60; 95% confidence interval [confidence interval]: 0.41-0.89; p\u2009=\u2009.005), and significant improvement in progression-free survival (hazard ratio 0.50; 95% confidence interval: 0.37-0.68; p\u2009<\u2009.001). In KEYNOTE-010, patients with disease progression on or after platinum-containing chemotherapy received pembrolizumab intravenously 2 mg/kg, 10 mg/kg, or docetaxel 75 mg/m2 every 3 weeks. "
        },
        {
            "id": "640c8309201352f04a000024_0001",
            "question": "The diagnosis of cholestasis is based on the elevations seen in what liver function tests?",
            "type": "list",
            "context": "The term cholestasis refers to bile acid retention, whether within the hepatocyte or in the bile ducts of any caliber. Biochemically, it is defined by a level of alkaline phosphatase that is 1.67-times higher than the upper limit of normal. Cholestatic diseases can be associated with an inflammatory process of the liver that destroys hepatocytes (hepatitis), withjaundice (yellowing of the skin and mucus membranes, associated with elevated serum bilirubin levels), or with both,"
        },
        {
            "id": "640c8309201352f04a000024_0002",
            "question": "The diagnosis of cholestasis is based on the elevations seen in what liver function tests?",
            "type": "list",
            "context": "Workup revealed elevated liver transaminases, alkaline phosphatase, and conjugated bilirubin"
        },
        {
            "id": "640c8309201352f04a000024_0003",
            "question": "The diagnosis of cholestasis is based on the elevations seen in what liver function tests?",
            "type": "list",
            "context": "he symptoms started about 1 week ago. Initial laboratory tests showed abnormal liver enzymes with elevated conjugated bilirubin and alkaline phosphatase suggestive of cholestatic jaundice. A"
        },
        {
            "id": "640c8309201352f04a000024_0004",
            "question": "The diagnosis of cholestasis is based on the elevations seen in what liver function tests?",
            "type": "list",
            "context": "The outcome was evaluated by monitoring clinical and biochemical markers of cholestasis, including alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, cholesterol, total serum tasting bile acids and total and conjugated bilirubin "
        },
        {
            "id": "6415c599690f196b51000013_0001",
            "question": "Which company produces Keytruda?",
            "type": "factoid",
            "context": "On October 24, 2016, the U.S. Food and Drug Administration (Food and Drug Administration) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non-small cell lung cancer (metastatic non-small cell lung cancer) whose tumors express programmed death-ligand 1 (programmed death-ligand 1) as determined by an Food and Drug Administration-approved test, as follows: (a) first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have high programmed death-ligand 1 expression (tumor proportion score [tumor proportion score] \u226550%), with no epidermal growth factor receptor (epidermal growth factor receptor) or anaplastic lymphoma kinase (anaplastic lymphoma kinase) genomic tumor aberrations, and (b) treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1 (tumor proportion score \u22651%), with disease progression on or after platinum-containing chemotherapy."
        },
        {
            "id": "6414638c201352f04a000047_0001",
            "question": "Cereblon (cereblon)  has been identified as the target for what type of drug?",
            "type": "factoid",
            "context": "Cereblon is a well-known target of thalidomide and its derivatives."
        },
        {
            "id": "6414638c201352f04a000047_0002",
            "question": "Cereblon (cereblon)  has been identified as the target for what type of drug?",
            "type": "factoid",
            "context": "We have identified novel cereblon inhibitors, namely DHFO and its analogs, with structural features that are slightly different from thalidomide but stronger cereblon-binding affinity. "
        },
        {
            "id": "6414638c201352f04a000047_0003",
            "question": "Cereblon (cereblon)  has been identified as the target for what type of drug?",
            "type": "factoid",
            "context": " It additionally modulates the anti-myeloma effect of the immunomodulatory drugs (immunomodulatory drugs) thalidomide, lenalidomide, and pomalidomide. immunomodulatory drugs bind to cereblon and recruit neo-substrates for their ubiquitination and proteasome-mediated degradation"
        },
        {
            "id": "6414638c201352f04a000047_0004",
            "question": "Cereblon (cereblon)  has been identified as the target for what type of drug?",
            "type": "factoid",
            "context": ". Cereblon (cereblon)-targeting immunomodulatory agents (immunomodulatory drugs\u00ae) lenalidomide (Lenacapavir) and pomalidomide (pomalidomide) play a central role in combination regimens due to their pleiotropic antitumor/immunomodulatory mechanisms that synergize with many anti-myeloma approved or developmental agents."
        },
        {
            "id": "6414638c201352f04a000047_0005",
            "question": "Cereblon (cereblon)  has been identified as the target for what type of drug?",
            "type": "factoid",
            "context": "Thalidomide, well known for its potent teratogenicity, has been re-evaluated as a clinically effective drug for the treatment of multiple myeloma. Although the direct target of thalidomide had been unclear until recently, we identified cereblon (cereblon) as a primary direct target of this drug b"
        },
        {
            "id": "6414638c201352f04a000047_0006",
            "question": "Cereblon (cereblon)  has been identified as the target for what type of drug?",
            "type": "factoid",
            "context": "The molecular mechanism of action of immunomodulatory drugs remained unclear for a long time until 2010 when the protein cereblon (cereblon) was identified as a primary direct target. immunomodulatory drugs binds to cereblon and alters the substrate specificity of the cereblon E3 ubiquitin ligase complex, "
        },
        {
            "id": "63f03a20f36125a42600001c_0001",
            "question": "Which drugs are included in the AZD7442?",
            "type": "list",
            "context": "AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab [AZD8895] and cilgavimab [AZD1061]), has been authorized for the prevention and treatment of coronavirus disease 2019 (coronavirus disease 2019). "
        },
        {
            "id": "63f03a20f36125a42600001c_0002",
            "question": "Which drugs are included in the AZD7442?",
            "type": "list",
            "context": "Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. "
        },
        {
            "id": "63f03a20f36125a42600001c_0003",
            "question": "Which drugs are included in the AZD7442?",
            "type": "list",
            "context": "Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality."
        },
        {
            "id": "63f03a20f36125a42600001c_0004",
            "question": "Which drugs are included in the AZD7442?",
            "type": "list",
            "context": "BACKGROUND: Intramuscular AZD7442 (Tixagevimab-Cilgavimab, (Evusheld)) has been found effective among immunocompromised individuals (immunocompromised individuals) in reducing Sars-Cov-2 infection and severe disease in ICIs. "
        },
        {
            "id": "640ddd9d201352f04a000028_0001",
            "question": "What were the first 2 programmed death 1 inhibitors approved by the Food and Drug Administration in 2014?",
            "type": "list",
            "context": "2 different programmed cell death protein 1 (programmed death 1) inhibitors, Nivolumab and Pembrolizumab."
        },
        {
            "id": "640ddd9d201352f04a000028_0002",
            "question": "What were the first 2 programmed death 1 inhibitors approved by the Food and Drug Administration in 2014?",
            "type": "list",
            "context": "The first monoclonal antibodies against the immune checkpoint programmed death 1 (programmed death 1) receptor, nivolumab and pembrolizumab, are now approved for clinical use"
        },
        {
            "id": "640ddd9d201352f04a000028_0003",
            "question": "What were the first 2 programmed death 1 inhibitors approved by the Food and Drug Administration in 2014?",
            "type": "list",
            "context": "e programmed cell death protein 1 (programmed death 1) inhibitors, nivolumab and pembrolizumab, have quickly been incorporated into clinical trials for first- and second-line therapy of Hodgkin lymphoma."
        },
        {
            "id": "640ddd9d201352f04a000028_0004",
            "question": "What were the first 2 programmed death 1 inhibitors approved by the Food and Drug Administration in 2014?",
            "type": "list",
            "context": "The first programmed death 1 (programmed death 1) inhibitor, pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab was previously approved in Japan. "
        },
        {
            "id": "6414c4cf690f196b51000006_0001",
            "question": "What is the difference between dermatillomania and skin picking disorder?",
            "type": "factoid",
            "context": "Dermatillomania or skin picking disorder (skin picking disorder) is a chronic, recurrent, and treatment resistant neuropsychiatric disorder with an underestimated prevalence that has a concerning negative impact on an individual's health and quality of life. "
        },
        {
            "id": "63eefa3bf36125a426000012_0001",
            "question": "What causes Japanese Spotted Fever?",
            "type": "factoid",
            "context": "Non-pathogenic Rickettsia species LON strains closely related to an agent of Japanese spotted fever (Japanese spotted fever), R. japonica, were isolated in Japan from Haemaphysalis longicornis ticks in 2001. "
        },
        {
            "id": "63eefa3bf36125a426000012_0002",
            "question": "What causes Japanese Spotted Fever?",
            "type": "factoid",
            "context": "Severe fever with thrombocytopenia syndrome (SFTS) and Japanese spotted fever (Japanese spotted fever; a spotted fever group rickettsiosis) are tick-borne zoonoses that are becoming a significant public health threat in Japan and East Asia."
        },
        {
            "id": "63eefa3bf36125a426000012_0003",
            "question": "What causes Japanese Spotted Fever?",
            "type": "factoid",
            "context": "Rickettsia japonica is a member of SFG rickettsiae causing Japanese spotted fever (Japanese spotted fever) and can transmit to humans via infected ticks. "
        },
        {
            "id": "6414c0f7690f196b51000001_0001",
            "question": "What are the clinical symptoms of an ornithine transcarbamylase deficiency?",
            "type": "list",
            "context": "X-linked ornithine transcarbamylase deficiency (ornithine transcarbamylase deficiency) is the most common urea cycle defect. The disease severity ranges from asymptomatic carrier state to severe neonatal presentation with hyperammonaemic encephalopathy. "
        },
        {
            "id": "6414c0f7690f196b51000001_0002",
            "question": "What are the clinical symptoms of an ornithine transcarbamylase deficiency?",
            "type": "list",
            "context": "Ornithine transcarbamylase deficiency (Ornithine transcarbamylase deficiency) is an X-linked metabolic disease and the most common urea cycle disorder. Due to high phenotypic heterogeneity, ranging from lethal neonatal hyperammonemic events to moderate symptoms and even asymptomatic individual"
        },
        {
            "id": "6414c0f7690f196b51000001_0003",
            "question": "What are the clinical symptoms of an ornithine transcarbamylase deficiency?",
            "type": "list",
            "context": "Deficiency of ornithine transcarbamylase, an enzyme in the urea cycle, results in hyperammonemia"
        },
        {
            "id": "6414c0f7690f196b51000001_0004",
            "question": "What are the clinical symptoms of an ornithine transcarbamylase deficiency?",
            "type": "list",
            "context": "extreme irritability (100 percent), episodic vomiting and lethargy (100 percent), protein avoidance (92 percent), ataxia (77 percent), Stage II coma (46 percent), delayed physical growth (38 percent), developmental delay (38 percent), and seizures"
        },
        {
            "id": "63eef60ef36125a42600000c_0001",
            "question": "Olokizumab is tested for which disease?",
            "type": "factoid",
            "context": "Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study."
        },
        {
            "id": "63eef60ef36125a42600000c_0002",
            "question": "Olokizumab is tested for which disease?",
            "type": "factoid",
            "context": "OBJECTIVE: To evaluate the efficacy and safety of olokizumab (olokizumab) in patients with active rheumatoid arthritis despite treatment with methotrexate (methotrexate)."
        },
        {
            "id": "63eef60ef36125a42600000c_0003",
            "question": "Olokizumab is tested for which disease?",
            "type": "factoid",
            "context": "CONCLUSIONS: Treatment with olokizumab was associated with significant improvement in signs, symptoms and physical function of rheumatoid arthritis without discernible differences between the two regimens. "
        },
        {
            "id": "63eef60ef36125a42600000c_0004",
            "question": "Olokizumab is tested for which disease?",
            "type": "factoid",
            "context": "Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis."
        },
        {
            "id": "63eef60ef36125a42600000c_0005",
            "question": "Olokizumab is tested for which disease?",
            "type": "factoid",
            "context": "BACKGROUND: The cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis."
        },
        {
            "id": "63eef60ef36125a42600000c_0006",
            "question": "Olokizumab is tested for which disease?",
            "type": "factoid",
            "context": "CONCLUSIONS: In patients with rheumatoid arthritis who were receiving maintenance methotrexate, olokizumab was superior to placebo and noninferior to adalimumab in producing an ACR20 response at 12 weeks. Larger and longer trials are required to determine the efficacy and safety of olokizumab in patients with rheumatoid arthritis. "
        },
        {
            "id": "63f03fc8f36125a426000021_0001",
            "question": "What disease can be treated with Lenacapavir?",
            "type": "factoid",
            "context": "Structural and Mechanistic Bases of Viral Resistance to human immunodeficiency virus type 1 Capsid Inhibitor Lenacapavir."
        },
        {
            "id": "63f03fc8f36125a426000021_0002",
            "question": "What disease can be treated with Lenacapavir?",
            "type": "factoid",
            "context": "Lenacapavir (Lenacapavir) is a long-acting, highly potent human immunodeficiency virus type 1 capsid (capsid) inhibitor. "
        },
        {
            "id": "63f03fc8f36125a426000021_0003",
            "question": "What disease can be treated with Lenacapavir?",
            "type": "factoid",
            "context": "The investigational drug lenacapavir accesses unoccupied hydrophobic pockets in the complex to potently impair human immunodeficiency virus type 1 inside the nucleus without displacing the tightly bound cellular cofactor from virus cores. "
        },
        {
            "id": "63f03fc8f36125a426000021_0004",
            "question": "What disease can be treated with Lenacapavir?",
            "type": "factoid",
            "context": "Lenacapavir (Sunlenca\u00ae) is a long-acting capsid inhibitor of human immunodeficiency virus type\u00a01 (human immunodeficiency virus type 1) being developed by Gilead Sciences Inc. "
        },
        {
            "id": "63f03fc8f36125a426000021_0005",
            "question": "What disease can be treated with Lenacapavir?",
            "type": "factoid",
            "context": "In August 2022, lenacapavir received its first approval in the EU for use in combination with other antiretroviral(s) in adults with multi-drug resistant HIV infection, for whom it is otherwise not possible to construct a suppressive anti-viral regimen. This article summarizes the milestones in the development of lenacapavir leading to this first approval for the treatment of human immunodeficiency virus type 1 infection."
        },
        {
            "id": "63f03fc8f36125a426000021_0006",
            "question": "What disease can be treated with Lenacapavir?",
            "type": "factoid",
            "context": "Lenacapavir: a first-in-class human immunodeficiency virus type 1 capsid inhibitor."
        },
        {
            "id": "63f03fc8f36125a426000021_0007",
            "question": "What disease can be treated with Lenacapavir?",
            "type": "factoid",
            "context": "PURPOSE OF REVIEW: This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle.RECENT FINDINGS: Lenacapavir demonstrated picomolar potency in vitro with no cross resistance to existing antiretroviral classes and potent antiviral activity in persons with human immunodeficiency virus type 1. In persons with human immunodeficiency virus type 1, there was no preexisting resistance to lenacapavir regardless of treatment history."
        },
        {
            "id": "63f03fc8f36125a426000021_0008",
            "question": "What disease can be treated with Lenacapavir?",
            "type": "factoid",
            "context": "In heavily treatment-experienced persons with multidrug-resistant human immunodeficiency virus type 1 and in treatment-naive persons with human immunodeficiency virus type 1, lenacapavir in combination with other antiretroviral agents led to high rates of virologic suppression and was well tolerated.SUMMARY: Ongoing studies are evaluating long-acting dosing of lenacapavir for treating human immunodeficiency virus type 1 in combination with other antiretrovirals and preventing human immunodeficiency virus type 1 as a single agent."
        },
        {
            "id": "64041701201352f04a000017_0001",
            "question": "What is the triad of the Eagle-Barrett Syndrome?",
            "type": "list",
            "context": "Eagle-Barrett Syndrome (Eagle-Barrett Syndrome) is a rare congenital condition characterized by the triad of absent or defective abdominal wall muscles, urinary tract abnormalities, and bilateral cryptorchidism."
        },
        {
            "id": "64041701201352f04a000017_0002",
            "question": "What is the triad of the Eagle-Barrett Syndrome?",
            "type": "list",
            "context": "BACKGROUND: Prune belly syndrome (Prune belly syndrome), also known as Eagle-Barrett syndrome (Eagle-Barrett syndrome), is a rare congenital disease characterized by deficiency or absence of abdominal wall muscles, urological abnormalities, and bilateral cryptorchidism."
        },
        {
            "id": "64041701201352f04a000017_0003",
            "question": "What is the triad of the Eagle-Barrett Syndrome?",
            "type": "list",
            "context": "Prune Belly syndrome (Prune belly syndrome) or Eagle-Barrett syndrome is an anatomo-radiological syndrome consisting of a complex and rare malformation characterized by the following triad of symptoms: deficiency of the abdominal muscles, malformations of the urinary tract, and bilateral cryptorchidism."
        },
        {
            "id": "64041701201352f04a000017_0004",
            "question": "What is the triad of the Eagle-Barrett Syndrome?",
            "type": "list",
            "context": "Prune belly syndrome (Prune belly syndrome), also known as Eagle-Barrett syndrome, is a rare congenital disorder characterized by absence or hypoplasia of the abdominal wall musculature, urinary tract anomalies, and cryptorchidism in males."
        },
        {
            "id": "640c85e9201352f04a000026_0001",
            "question": "What cells proliferate in Mantle Cell Lymphoma",
            "type": "factoid",
            "context": "Mantle cell lymphoma (Mantle cell lymphoma) is a relatively rare B-cell non-Hodgkin lymphoma, typically presenting with extensive lymphadenopathy,"
        },
        {
            "id": "640c85e9201352f04a000026_0002",
            "question": "What cells proliferate in Mantle Cell Lymphoma",
            "type": "factoid",
            "context": "Activity has been demonstrated in many subtypes of B-cell lymphoma, including diffuse large cell lymphoma, follicular lymphoma (follicular lymphoma), mantle cell lymphoma (Mantle cell lymphoma), chronic lymphocytic leukemia (chronic lymphocytic leukemia), lymphocyte-predominant Hodgkin lymphoma, and Waldenstr\u00f6m macroglobulinemia (WM)"
        },
        {
            "id": "640c85e9201352f04a000026_0003",
            "question": "What cells proliferate in Mantle Cell Lymphoma",
            "type": "factoid",
            "context": "Mantle cell lymphoma (Mantle cell lymphoma) is a subtype of B-cell non-Hodgkin's lymphoma seen predominantly in males. "
        },
        {
            "id": "6415bb3c690f196b5100000e_0001",
            "question": "What is the estimated cost reduction when using telegenetics?",
            "type": "factoid",
            "context": "We estimated reduced time and costs by online counseling with about 8% and 10-12%, respectively."
        },
        {
            "id": "63f03ae6f36125a42600001d_0001",
            "question": "What is the target of BI 1015550?",
            "type": "factoid",
            "context": "METHODS: In this phase 2, double-blind, placebo-controlled trial, we investigated the efficacy and safety of BI 1015550, an oral preferential inhibitor of the PDE4B subtype, in patients with idiopathic pulmonary fibrosis."
        },
        {
            "id": "63f03ae6f36125a42600001d_0002",
            "question": "What is the target of BI 1015550?",
            "type": "factoid",
            "context": "Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis."
        },
        {
            "id": "63f03ae6f36125a42600001d_0003",
            "question": "What is the target of BI 1015550?",
            "type": "factoid",
            "context": "Introduction: BI 1015550 is a phosphodiesterase 4 (phosphodiesterase 4) inhibitor that has antifibrotic properties. "
        },
        {
            "id": "63f03ae6f36125a42600001d_0004",
            "question": "What is the target of BI 1015550?",
            "type": "factoid",
            "context": "BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis."
        },
        {
            "id": "63f03ae6f36125a42600001d_0005",
            "question": "What is the target of BI 1015550?",
            "type": "factoid",
            "context": "BI 1015550 is a novel phosphodiesterase 4 inhibitor showing a preferential enzymatic inhibition of PDE4B."
        },
        {
            "id": "63f03ae6f36125a42600001d_0006",
            "question": "What is the target of BI 1015550?",
            "type": "factoid",
            "context": "In summary, the unique preferential inhibition of PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibrotic potential, suggest BI 1015550 to be a promising oral clinical candidate for the treatment of IPF and other fibro-proliferative diseases."
        },
        {
            "id": "63eeeaaaf36125a426000004_0001",
            "question": "Beremagene Geperpavec is tested for which disease?",
            "type": "factoid",
            "context": "Recessive dystrophic epidermolysis bullosa (Recessive dystrophic epidermolysis bullosa) is a lifelong genodermatosis associated with blistering, wounding, and scarring caused by mutations in COL7A1, the gene encoding the anchoring fibril component, collagen VII (C7). Here, we evaluated beremagene geperpavec (B-VEC), an engineered, non-replicating COL7A1 containing herpes simplex virus type 1 (herpes simplex virus type 1) vector, to treat Recessive dystrophic epidermolysis bullosa skin. "
        },
        {
            "id": "63eeeaaaf36125a426000004_0002",
            "question": "Beremagene Geperpavec is tested for which disease?",
            "type": "factoid",
            "context": "These studies show that B-VEC is an easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with Recessive dystrophic epidermolysis bullosa."
        },
        {
            "id": "64138ce8201352f04a000042_0001",
            "question": "Hairpatches is a single gene mutation associated with what disease?",
            "type": "factoid",
            "context": "\"Hairpatches\" (Hairpatches\") is a naturally occurring, autosomal semi-dominant mouse mutation. Hairpatches\"/Hairpatches\" homozygotes die in utero, while Hairpatches\"/+ heterozygotes exhibit progressive renal failure accompanied by patchy alopecia. "
        },
        {
            "id": "64138ce8201352f04a000042_0002",
            "question": "Hairpatches is a single gene mutation associated with what disease?",
            "type": "factoid",
            "context": "Hairpatches, a single gene mutation characterized by progressive renal disease and alopecia in the mouse. A potential model for a newly described heritable human disorder."
        },
        {
            "id": "63f9cd0b33942b094c000010_0001",
            "question": "What is the alternative microexon splicing by RBFOX2 and PTBP1 associated with?",
            "type": "factoid",
            "context": "Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer."
        },
        {
            "id": "63f9cd0b33942b094c000010_0002",
            "question": "What is the alternative microexon splicing by RBFOX2 and PTBP1 associated with?",
            "type": "factoid",
            "context": "Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer."
        },
        {
            "id": "63f9cd0b33942b094c000010_0003",
            "question": "What is the alternative microexon splicing by RBFOX2 and PTBP1 associated with?",
            "type": "factoid",
            "context": "RNA interference-mediated knockdown experiments identified two splicing factors, RBFOX2 and PTBP1, as regulators of microexon splicing in CRC cells. RBFOX2 and PTBP1 were found to directly bind to microexon-containing pre-mRNAs and to control their splicing in such cells. Differential microexon splicing was shown to be due, at least in part, to altered expression of RBFOX2 and PTBP1 in CRC tissue compared to matched normal tissue. "
        },
        {
            "id": "63f9cd0b33942b094c000010_0004",
            "question": "What is the alternative microexon splicing by RBFOX2 and PTBP1 associated with?",
            "type": "factoid",
            "context": "Our data thus suggest that altered expression of RBFOX2 and PTBP1 might influence CRC metastasis through the regulation of microexon splicing."
        },
        {
            "id": "63f56f7533942b094c000002_0001",
            "question": "Which gene is implicated in Canavan disease?",
            "type": "factoid",
            "context": "Cribriform Appearance of White Matter in Canavan Disease Associated with Novel Mutations of aspartoacylase Gene."
        },
        {
            "id": "63f56f7533942b094c000002_0002",
            "question": "Which gene is implicated in Canavan disease?",
            "type": "factoid",
            "context": "Genetic analysis revealed novel mutations in the aspartoacylase or aspartoacylase gene that possibly accounts for the severe form of Canavan disease, which probably explains the imaging findings."
        },
        {
            "id": "63f56f7533942b094c000002_0003",
            "question": "Which gene is implicated in Canavan disease?",
            "type": "factoid",
            "context": "Canavan disease (Canavan disease) is an inherited leukodystrophy resulting from mutations in the gene encoding aspartoacylase (aspartoacylase). "
        },
        {
            "id": "63f56f7533942b094c000002_0004",
            "question": "Which gene is implicated in Canavan disease?",
            "type": "factoid",
            "context": "Canavan disease (Canavan disease) is a devastating neurological disease that lacks effective therapy. Because Canavan disease is caused by mutations of the aspartoacylase (aspartoacylase) gene, we introduced the wild-type (wild-type) aspartoacylase gene into patient iPSCs through lentiviral transduction or CRISPR/Cas9-mediated gene editing. "
        },
        {
            "id": "63f56f7533942b094c000002_0005",
            "question": "Which gene is implicated in Canavan disease?",
            "type": "factoid",
            "context": "The compound heterozygous variants of the aspartoacylase gene probably underlay the Canavan disease in this patient, and the result has enabled prenatal diagnosis for this family."
        },
        {
            "id": "63eeeb70f36125a426000005_0001",
            "question": "What disease can be treated with Glofitamab?",
            "type": "factoid",
            "context": "Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy."
        },
        {
            "id": "63eeeb70f36125a426000005_0002",
            "question": "What disease can be treated with Glofitamab?",
            "type": "factoid",
            "context": "In this study, we evaluated the safety and efficacy of a monotherapy with the bispecific CD20xCD3 antibody glofitamab in patients who progressed after CAR T treatment. We report nine consecutive patients with progressive DLBCL after preceding CAR T-cell therapy. "
        },
        {
            "id": "63eeeb70f36125a426000005_0003",
            "question": "What disease can be treated with Glofitamab?",
            "type": "factoid",
            "context": "Our data suggest that glofitamab treatment is well tolerated and effective in patients with DLBCL relapsing after CAR T-cell therapy and can enhance residual CAR T-cell activity."
        },
        {
            "id": "63eeeb70f36125a426000005_0004",
            "question": "What disease can be treated with Glofitamab?",
            "type": "factoid",
            "context": "Bispecific antibodies such as epcoritamab, mosunetuzumab, and glofitamab, anti-CD19 antibody drug tafasitamab combined with lenalidomide, CD19 antibody drug conjugate loncastuximab tesirine, oral selective inhibitor of nuclear export selinexor, and several new agents have been investigated for DLBCL. "
        },
        {
            "id": "63eeeb70f36125a426000005_0005",
            "question": "What disease can be treated with Glofitamab?",
            "type": "factoid",
            "context": "Glofitamab, a novel CD20xCD3, T-cell-engaging bispecific antibody, exhibited single-agent activity in Study NP30179, a first-in-human, phase 1 trial in relapsed/refractory B-cell non-Hodgkin lymphoma."
        }
    ]
}